Thermo Fisher Scientific announced the acquisition of Henogen, a Belgian viral vector manufacturing business belonging to Groupe Novasep, for about $875m.
Thermo Fisher Acquires Novasep s Viral Vector Manufacturing Business For 725 Mln Euros
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Thermo Fisher Scientific Inc. (TMO) has completed the acquisition of Henogen S.A., Groupe Novasep SAS s viral vector manufacturing business in Belgium for about 725 million euros in cash, the two companies said Friday.
Novasep s viral vector manufacturing business provides contract manufacturing services for vaccines and therapies to biotechnology companies as well as large biopharma customers. The business will be part of Thermo Fisher s Pharma Services business within the Laboratory Products and Services Segment.
Novasep s viral vector business has two locations in Seneffe and Gosselies, Belgium. It offers more than 7,000 square meters of clinical and commercial manufacturing capacity.
The growing global pipeline of cell and gene therapy projects has prompted Thermo Fisher Scientific to invest again, with it announcing today that it had bought Henogen, Novasep’s viral vector manufacturing business based in Belgium, for about US$879.72m (€725m) in cash.